At-home BCG treatment with digital support for bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project has two cohorts: a qualitative arm that interviews patients and stakeholders about barriers and facilitators to intravesical treatment adherence, and a pilot arm that creates and tests an at‑home BCG delivery program. Pilot participants receive home-based intravesical BCG under a protocol and use a conversational agent on their mobile phone to report symptoms, quality of life, and receive self‑management support. The qualitative cohort includes adults who completed intravesical therapy or experienced providers to inform program design, while the pilot cohort enrolls adults newly prescribed BCG who can undergo catheterization and use English-language mobile messaging. Procedures are managed through Abramson Cancer Center with remote monitoring and scheduled clinic oversight to track safety and adherence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Inclusion criteria for patients in Cohort 1

* Age 18 years or older;
* completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders
* Age 18 years or older;
* experience with the delivery of BCG delivery for more than 2 years

Cohort 2 inclusion criteria

* Age 18 years or older;
* diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy

Exclusion Criteria:

Cohort 1 exclusion criteria

• inability to provide informed consent

Cohort 2 exclusion criteria

* inability to provide informed consent
* inability to undergo catheterization (i.e. - history of urethral stricture)
* inability to receive BCG therapy (i.e. - previous reaction with BCG)
* no access to mobile phone
* inability to respond to written conversations in English

Where it's running

• Abramson Cancer Center
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Daniel Lee, PI, MD
• Email: daniel.lee4@pennmedicine.upenn.edu
• Phone: 215-615-3780

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.